These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 28836054)

  • 21. Impact of ABCB1 Gene Polymorphisms and Smoking on the Susceptibility Risk of Chronic Myeloid Leukemia and Cytogenetic Response.
    Mohammadi F; Shafiei M; Assad D; Rostami G; Hamid M; Foroughmand AM
    Iran Biomed J; 2021 Jan; 25(1):54-61. PubMed ID: 33129240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical impact of ABCC1 and ABCC2 genotypes and haplotypes in mediating imatinib resistance among chronic myeloid leukaemia patients.
    Au A; Baba AA; Azlan H; Norsa'adah B; Ankathil R
    J Clin Pharm Ther; 2014 Dec; 39(6):685-90. PubMed ID: 25060527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients.
    Elghannam DM; Ibrahim L; Ebrahim MA; Azmy E; Hakem H
    Hematology; 2014 Apr; 19(3):123-8. PubMed ID: 23683876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis.
    Jiang ZP; Zhao XL; Takahashi N; Angelini S; Dubashi B; Sun L; Xu P
    Pharmacogenomics; 2017 Jan; 18(1):35-56. PubMed ID: 27991849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. C1236T polymorphism in MDR1 gene correlates with therapeutic response to imatinib mesylate in Indian patients with chronic myeloid leukaemia.
    Chhikara S; Sazawal S; Mishra P; Chaubey R; Mahapatra M; Saxena R
    Natl Med J India; 2015; 28(6):272-5. PubMed ID: 27294449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of ABCB1, ABCG2 drug transporter polymorphisms and smoking with disease risk and cytogenetic response to imatinib in chronic myeloid leukemia patients.
    Mohammadi F; Rostami G; Hamid M; Shafiei M; Azizi M; Bahmani H
    Leuk Res; 2023 Mar; 126():107021. PubMed ID: 36696828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia.
    Ni LN; Li JY; Miao KR; Qiao C; Zhang SJ; Qiu HR; Qian SX
    Med Oncol; 2011 Mar; 28(1):265-9. PubMed ID: 20204543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis.
    Zheng Q; Wu H; Yu Q; Kim DH; Lipton JH; Angelini S; Soverini S; Vivona D; Takahashi N; Cao J
    Pharmacogenomics J; 2015 Apr; 15(2):127-34. PubMed ID: 25245580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
    Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
    Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment.
    Jaruskova M; Curik N; Hercog R; Polivkova V; Motlova E; Benes V; Klamova H; Pecherkova P; Belohlavkova P; Vrbacky F; Machova Polakova K
    J Exp Clin Cancer Res; 2017 Apr; 36(1):55. PubMed ID: 28420426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment.
    Eadie LN; Dang P; Saunders VA; Yeung DT; Osborn MP; Grigg AP; Hughes TP; White DL
    Leukemia; 2017 Jan; 31(1):75-82. PubMed ID: 27416909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia.
    Cheng F; Cui Z; Li Q; Chen S; Li W; Zhang Y
    Int Immunopharmacol; 2024 May; 133():112090. PubMed ID: 38640718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multidrug resistance gene (MDR1) polymorphisms may not be directly associated with response to imatinib in chronic myeloid leukemia.
    Wang JL; Liu HJ; Li F; Yang WY; Wang JM; Tan SF; Wang Q
    Genet Mol Res; 2015 Nov; 14(4):14967-78. PubMed ID: 26634458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
    Bedewy AM; El-Maghraby SM
    Hematology; 2013 Jul; 18(4):211-6. PubMed ID: 23394475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia.
    de Lima LT; Vivona D; Bueno CT; Hirata RD; Hirata MH; Luchessi AD; de Castro FA; de Lourdes F Chauffaille M; Zanichelli MA; Chiattone CS; Hungria VT; Guerra-Shinohara EM
    Med Oncol; 2014 Mar; 31(3):851. PubMed ID: 24469953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.
    Seong SJ; Lim M; Sohn SK; Moon JH; Oh SJ; Kim BS; Ryoo HM; Chung JS; Joo YD; Bang SM; Jung CW; Kim DH; Park SY; Yoon SS; Kim I; Lee HG; Won JH; Min YH; Cheong JW; Park JS; Eom KS; Hyun MS; Kim MK; Kim H; Park MR; Park J; Kim CS; Kim HJ; Kim YK; Park EK; Zang DY; Jo DY; Lee HW; Yoon YR
    Ann Oncol; 2013 Mar; 24(3):756-60. PubMed ID: 23117072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PDGFRα promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thrombocytopenia in chronic myeloid leukemia: A study from India.
    Guru SA; Mir R; Bhat M; Najar I; Zuberi M; Sumi M; Masroor M; Gupta N; Saxena A
    Tumour Biol; 2017 Oct; 39(10):1010428317713857. PubMed ID: 29019285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between ABCB1 polymorphisms and response to first-generation antiepileptic drugs in a Tunisian epileptic population.
    Ajmi M; Boujaafar S; Zouari N; Amor D; Nasr A; Rejeb NB; Amor SB; Omezzine A; Benammou S; Bouslama A
    Int J Neurosci; 2018 Aug; 128(8):705-714. PubMed ID: 29198163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia.
    Vine J; Cohen SB; Ruchlemer R; Goldschmidt N; Levin M; Libster D; Gural A; Gatt ME; Lavie D; Ben-Yehuda D; Rund D
    Leuk Lymphoma; 2014 Nov; 55(11):2525-31. PubMed ID: 24524306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis.
    Zu B; Li Y; Wang X; He D; Huang Z; Feng W
    Pharmacogenomics; 2014 Apr; 15(5):667-77. PubMed ID: 24798723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.